慢加急性肝衰竭的定义、预后评估及诊治进展

毕占虎; 王临旭; 连建奇

doi:10.3969/j.issn.1001-5256.2022.07.041

慢加急性肝衰竭的定义、预后评估及诊治进展

DOI: 10.3969/j.issn.1001-5256.2022.07.041

空军军医大学第二附属医院传染科，西安 710038

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：毕占虎负责撰写论文；王临旭负责修改论文；连建奇负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
连建奇，lianjq@fmmu.edu.cn

计量
- 文章访问数: 1062
- HTML全文浏览量: 185
- PDF下载量: 250
- 被引次数: 0
出版历程
- 收稿日期: 2022-01-04
- 出版日期: 2022-07-20

Definition, prognostic assessment, and advances in the diagnosis and treatment of acute-on-chronic liver failure

Department of Infectious Diseases, The Second Affiliated Hospital of Air Force Medical University, Xi'an 710038, China

More Information

Corresponding author: LIAN Jianqi, lianjq@fmmu.edu.cn

摘要

摘要: 慢加急性肝衰竭(ACLF)是一种在慢性肝病基础上发生肝功能急性失代偿的临床综合征，目前全球尚无统一定义标准。其显著特征是肝病进展迅速，常伴发多器官功能衰竭，短期病死率高。慢性肝病以慢性病毒性肝炎和酒精性肝病最为常见。感染、酒精、肝毒性药物等是其发生的主要诱因，但有高达40%~50%的ACLF病例没有可识别的诱发因素。早期发现并准确评估病情对ACLF患者至关重要，但目前仍缺乏早期预警并准确评估病情的理想方法。目前的治疗方法主要为器官支持和并发症的治疗，肝移植是唯一能够改善预后的治疗手段，但如何选择合适的患者以及肝移植的时机仍存在一定争议。
- 慢加急性肝衰竭 /
- 预后 /
- 诊断 /
- 治疗学
Abstract: Acute-on-chronic liver failure (ACLF) is a clinical syndrome with acute decompensation of liver function on the basis of chronic liver diseases, and at present, there is still no unified definition standard for this disease in the world. ACLF is characterized by rapid progression of liver disease, multiple organ failure, and high short-term mortality. Chronic viral hepatitis and alcoholic liver disease are the most common chronic liver diseases, and infection, alcohol, and hepatotoxic drugs are the main predisposing factors for this disease, but up to 40%-50% of ACLF cases have no identifiable predisposing factors. Early identification and accurate assessment of disease conditions are crucial to ACLF patients, but there is still a lack of ideal assessment methods for early warning and accurate assessment. Currently, the main treatment methods are organ support and treatment of complications, and liver transplantation is the only treatment method that can improve prognosis; however, there are still controversies over the selection of appropriate patients and the timing of liver transplantation.
- Acute-on-Chronic Liver Failure /
- Prognosis /
- Diagnosis /
- Therapeutics

HTML全文

表 1 ACLF患者的预后评分系统

Table 1. Prognostic scoring systems used in patients with ACLF

评分系统	年份	开发目的	评价指标	评分公式
CTP	1964年	预测门静脉曲张手术风险	HE、腹水、TBil、Alb、PT	无
MELD	2000年	评估行TIPS的肝硬化患者短期预后	TBil、INR、Cr、病因	3.8×ln TBil+11.2×ln INR+9.6×ln Cr+6.4×病因(胆汁性或酒精性0、其他1)
MELD-Na	2006年	MELD评分的发展	TBil、INR、Cr、病因、血清Na⁺	MELD+1.59×(135 -血清Na⁺)
iMELD	2007年	MELD评分的发展	TBil、INR、Cr、病因、血清Na⁺、年龄	MELD+(0.3×年龄)-(0.7×血清Na⁺)+100
CLIF-SOFA	2013年	专门用于评估ACLF患者预后	TBil、Cr、HE分级、INR、平均动脉压、PaO₂/FiO₂或SpO₂/FiO₂	无
CLIF-C OF	2014年	CLIF-C SOFA的简化版，用于ACLF诊断和分级	TBil、Cr、HE分级、INR、平均动脉压、PaO₂/FiO₂或SpO₂/FiO₂	无
CLIF-C ACLF	2014年	评价ACLF预后	TBil、Cr、HE分级、INR、平均动脉压、PaO₂/FiO₂或SpO₂/FiO₂、年龄、WBC	10×(0.33×CLIF-OF+0.04×年龄+0.63×ln WBC-2)
COSSH-ACLF	2018年	评价HBV-ACLF预后	TBil、Cr、HE分级、INR、平均动脉压、PaO₂/FiO₂或SpO₂/FiO₂、年龄	0.741×INR+0.523×HBV-SOFA+0.026×年龄+0.003×TBil
注：TIPS，经颈静脉肝内门体分流术；Cr，肌酐；PaO₂，氧分压；FiO₂，吸入气体氧含量；SpO₂，动脉血氧饱和度。

下载: 导出CSV

参考文献(51)

[1]	WU T, LI J, SHAO L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut, 2018, 67(12): 2181-2191. DOI: 10.1136/gutjnl-2017-314641.
[2]	SARIN SK, KEDARISETTY CK, ABBAS Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J]. Hepatol Int, 2014, 8(4): 453-471. DOI: 10.1007/s12072-014-9580-2.
[3]	SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3.
[4]	MOREAU R, JALAN R, GINES P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144(7): 1426-1437, 1437. e1-9. DOI: 10.1053/j.gastro.2013.02.042.
[5]	BAJAJ JS, O'LEARY JG, REDDY KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures[J]. Hepatology, 2014, 60(1): 250-256. DOI: 10.1002/hep.27077.
[6]	O'LEARY JG, REDDY KR, GARCIA-TSAO G, et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis[J]. Hepatology, 2018, 67(6): 2367-2374. DOI: 10.1002/hep.29773.
[7]	HERNAEZ R, KRAMER JR, LIU Y, et al. Prevalence and short-term mortality of acute-on-chronic liver failure: a national cohort study from the USA[J]. J Hepatol, 2019, 70(4): 639-647. DOI: 10.1016/j.jhep.2018.12.018.
[8]	BAJAJ JS, O'LEARY JG, LAI JC, et al. Acute-on-chronic liver failure clinical guidelines[J]. Am J Gastroenterol, 2022, 117(2): 225-252. DOI: 10.14309/ajg.0000000000001595.
[9]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Arificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[10]	FERNÁNDEZ J, ACEVEDO J, WIEST R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis[J]. Gut, 2018, 67(10): 1870-1880. DOI: 10.1136/gutjnl-2017-314240.
[11]	MVCKE MM, RUMYANTSEVA T, MVCKE VT, et al. Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality[J]. Liver Int, 2018, 38(4): 645-653. DOI: 10.1111/liv.13568.
[12]	LIU XQ, ZHANG XY, YING Y, et al. The role of prophylactic antibiotics in hepatitis B virus-related acute-on-chronic liver failure patients at risk of bacterial infection: a retrospective study[J]. Infect Dis Poverty, 2021, 10(1): 44. DOI: 10.1186/s40249-021-00830-7.
[13]	ZACCHERINI G, WEISS E, MOREAU R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment[J]. JHEP Rep, 2021, 3(1): 100176. DOI: 10.1016/j.jhepr.2020.100176.
[14]	LIU XY, HU JH, LI C, et al. Clinical features of patients with acute-on-chronic liver failure and bacterial infection and influencing factors for prognosis[J]. J Clin Hepatol, 2021, 37(9): 2148-2152. DOI: 10.3969/j.issn.1001-5256.2021.09.028. 刘晓燕, 胡瑾华, 李晨, 等. 慢加急性肝衰竭合并细菌感染患者的临床特征及预后影响因素分析[J]. 临床肝胆病杂志, 2021, 37(9): 2148-2152. DOI: 10.3969/j.issn.1001-5256.2021.09.028.
[15]	TREBICKA J, BORK P, KRAG A, et al. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 167-180. DOI: 10.1038/s41575-020-00376-3.
[16]	BERNAL W, JALAN R, QUAGLIA A, et al. Acute-on-chronic liver failure [J]. The Lancet, 2015, 386(10003): 1576-1587. DOI: 10.1016/s0140-6736(15)00309-8.
[17]	LO RE V 3rd, CARBONARI DM, LEWIS JD, et al. Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status[J]. Am J Med, 2016, 129(3): 283-291. e5. DOI: 10.1016/j.amjmed.2015.10.029.
[18]	CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study[J]. Gastroenterology, 2015, 148(7): 1340-1352. e7. DOI: 10.1053/j.gastro.2015.03.006.
[19]	DEVARBHAVI H, CHOUDHURY AK, SHARMA MK, et al. Drug-induced acute-on-chronic liver failure in asian patients[J]. Am J Gastroenterol, 2019, 114(6): 929-937. DOI: 10.14309/ajg.0000000000000201.
[20]	SUNDARAM V, JALAN R, AHN JC, et al. Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(3): 617-625. DOI: 10.1016/j.jhep.2018.04.016.
[21]	DUSEJA A, DE A, TANEJA S, et al. Impact of metabolic risk factors on the severity and outcome of patients with alcohol-associated acute-on-chronic liver failure[J]. Liver Int, 2021, 41(1): 150-157. DOI: 10.1111/liv.14671.
[22]	LIU CR, LI YP, LUO S, et al. Influencing factors for the short-term prognosis of patients with HBV-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(1): 56-62. DOI: 10.3969/j.issn.1001-5256.2021.01.012. 刘晨瑞, 李亚萍, 罗森, 等. HBV相关慢加急性肝衰竭患者短期预后的影响因素分析[J]. 临床肝胆病杂志, 2021, 37(1): 56-62. DOI: 10.3969/j.issn.1001-5256.2021.01.012.
[23]	PUGH RNH, MURRAY-LYON IM, DAWSON JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973, 60: 646-649.
[24]	MALINCHOC M, KAMATH PS, GORDON FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31(4): 864-871. DOI: 10.1053/he.2000.5852.
[25]	BIGGINS SW, KIM WR, TERRAULT NA, et al. Evidence-based incorporation of serum sodium concentration into MELD[J]. Gastroenterology, 2006, 130(6): 1652-1660. DOI: 10.1053/j.gastro.2006.02.010.
[26]	LUCA A, ANGERMAYR B, BERTOLINI G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis[J]. Liver Transpl, 2007, 13(8): 1174-1180. DOI: 10.1002/lt.21197.
[27]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[28]	KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470. DOI: 10.1053/jhep.2001.22172.
[29]	HERNAEZ R, LIU Y, KRAMER JR, et al. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure[J]. J Hepatol, 2020, 73(6): 1425-1433. DOI: 10.1016/j.jhep.2020.06.005.
[30]	ABDALLAH MA, KUO YF, ASRANI S, et al. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality[J]. J Hepatol, 2021, 74(6): 1355-1361. DOI: 10.1016/j.jhep.2020.12.003.
[31]	VINCENT JL, MORENO R, TAKALA J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine[J]. Intensive Care Med, 1996, 22(7): 707-710. DOI: 10.1007/BF01709751.
[32]	ZHENG YX, ZHONG X, LI YJ, et al. Performance of scoring systems to predict mortality of patients with acute-on-chronic liver failure: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2017, 32(10): 1668-1678. DOI: 10.1111/jgh.13786.
[33]	ZHANG Y, NIE Y, LIU L, et al. Assessing the prognostic scores for the prediction of the mortality of patients with acute-on-chronic liver failure: a retrospective study[J]. Peer J, 2020, 8: e9857. DOI: 10.7717/peerj.9857.
[34]	JALAN R, SALIBA F, PAVESI M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure[J]. J Hepatol, 2014, 61(5): 1038-1047. DOI: 10.1016/j.jhep.2014.06.012.
[35]	LI N, HUANG C, YU KK, et al. Validation of prognostic scores to predict short-term mortality in patients with HBV-related acute-on-chronic liver failure: The CLIF-C OF is superior to MELD, CLIF SOFA, and CLIF-C ACLF[J]. Medicine (Baltimore), 2017, 96(17): e6802. DOI: 10.1097/MD.0000000000006802.
[36]	BAROSA R, ROQUE RAMOS L, PATITA M, et al. CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on chronic liver failure admitted to the ward[J]. Rev Esp Enferm Dig, 2017, 109(6): 399-405. DOI: 10.17235/reed.2017.4701/2016.
[37]	TONG JJ, ZHAO W, MU XY, et al. Predictive value of the Chinese group on the study of severe hepatitis B-acute-on-chronic liver failure score in the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Chin Med J (Engl), 2019, 132(13): 1541-1549. DOI: 10.1097/CM9.0000000000000298.
[38]	HERNAEZ R, SOLÀ E, MOREAU R, et al. Acute-on-chronic liver failure: an update[J]. Gut, 2017, 66(3): 541-553. DOI: 10.1136/gutjnl-2016-312670.
[39]	SOLÉ C, GUILLY S, DA SILVA K, et al. Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis[J]. Gastroenterology, 2021, 160(1): 206-218. e13. DOI: 10.1053/j.gastro.2020.08.054.
[40]	ARROYO V, MOREAU R, JALAN R, et al. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis[J]. J Hepatol, 2015, 62(1 Suppl): S131-S143. DOI: 10.1016/j.jhep.2014.11.045.
[41]	LIU H, ZHANG Q, LIU L, et al. Effect of artificial liver support system on short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Artif Organs, 2020, 44(10): E434-E447. DOI: 10.1111/aor.13710.
[42]	HUANG K, JI F, XIE Z, et al. Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis[J]. Sci Rep, 2019, 9(1): 16462. DOI: 10.1038/s41598-019-53029-0.
[43]	Transplantation Immunology Committee of Branch of Organ Transplantation Physician of Chinese Medical Doctor Association, Enhanced Recovery of Liver Transplantation Group of Enhanced Recovery after Surgery Committee of Chinese Research Hospital Society. Expert consensus on perioperative management of liver transplantation in adults with acute-on-chronic liver failure[J]. Ogran Transplant, 2020, 11(5): 533-542. DOI: 10.3969/j.issn.1674-7445.2020.05.001. 中国医师协会器官移植医师分会移植免疫学专业委员会, 中国研究型医院学会加速康复外科委员会肝移植加速康复学组. 成人慢加急性肝衰竭肝移植围手术期管理专家共识[J]. 器官移植, 2020, 11(5): 533-542. DOI: 10.3969/j.issn.1674-7445.2020.05.001.
[44]	SUNDARAM V, MAHMUD N, PERRICONE G, et al. Longterm outcomes of patients undergoing liver transplantation for acute-on-chronic liver failure[J]. Liver Transpl, 2020, 26(12): 1594-1602. DOI: 10.1002/lt.25831.
[45]	SUNDARAM V, JALAN R, WU T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation[J]. Gastroenterology, 2019, 156(5): 1381-1391. e3. DOI: 10.1053/j.gastro.2018.12.007.
[46]	TOMESCU D, POPESCU M, BIANCOFIORE G. Liver transplantation for acute-on-chronic liver failure[J]. Best Pract Res Clin Anaesthesiol, 2020, 34(1): 25-33. DOI: 10.1016/j.bpa.2019.12.001.
[47]	HUEBENER P, STERNECK MR, BANGERT K, et al. Stabilisation of acute-on-chronic liver failure patients before liver transplantation predicts post-transplant survival[J]. Aliment Pharmacol Ther, 2018, 47(11): 1502-1510. DOI: 10.1111/apt.14627.
[48]	FAN Q, LI Z. Liver transplantation for acute-on-chronic liver failure[J]. Organ Transplantat, 2022, 13(3): 333-337. DOI: 10.3969/j.issn.1674-7445.2022.03.008. 范祺, 李照. 慢加急性肝衰竭的肝移植治疗[J]. 器官移植, 2022, 13(3): 333-337. DOI: 10.3969/j.issn.1674-7445.2022.03.008.
[49]	SHI M, ZHANG Z, XU R, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients[J]. Stem Cells Transl Med, 2012, 1(10): 725-731. DOI: 10.5966/sctm.2012-0034.
[50]	GARG V, GARG H, KHAN A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure[J]. Gastroenterology, 2012, 142(3): 505-512. e1. DOI: 10.1053/j.gastro.2011.11.027.
[51]	ENGELMANN C, HERBER A, FRANKE A, et al. Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)[J]. J Hepatol, 2021, 75(6): 1346-1354. DOI: 10.1016/j.jhep.2021.07.033.